AMGN · Earnings call · 2026Q3T · Full report
EVENITY Market Demand
AMGEN INC · 2026-11-03 · Importance 52 · Surprise 56 · No source text
EVENITY sales increased 39% year-over-year to $751 million, following 38% growth in the previous quarter. In the United States, demand was supported by an expanding prescriber base and deeper physician adoption, and Amgen is increasing investment to extend physician reach and patient access. In Japan, EVENITY holds nearly 60% volume share in the bone-builder category, with updated guidelines and use among treatment-naive patients supporting growth.
Key facts
- EVENITY sales increased 39% in Q3 2026 to $751 million.
- EVENITY had 38% year-over-year growth in the previous quarter.
- In Japan, EVENITY had nearly 60% volume share in the bone-builder category.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +2.1% | EVENITY sales increased 39% in Q3 2026 to $751 million. |